Novo Nordisk | NVO - Ebitda


Novo Nordisk reported DKK31.44B in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
ANI Pharmaceuticals USD 59.6M 5.52M Sep/2025
Aurora Cannabis CAD 15.37M 26.8M Sep/2025
Bausch Health Companies USD 986M 74M Sep/2025
Bristol-Myers Squibb USD 4.24B 967M Sep/2025
Canopy Growth CAD 16.62M 38.45M Sep/2025
Corcept Therapeutics USD 10.7M 16.45M Sep/2025
Drreddys Laboratories INR 21.59B 1.49B Dec/2025
Eli Lilly USD 7.88B 378.1M Sep/2025
GlaxoSmithKline GBP 3.36B 179M Sep/2025
Merck USD 8.39B 1.97B Sep/2025
Nektar Therapeutics USD -31.81M 70K Sep/2023
Novartis USD 5.88B 290M Sep/2025
Novo Nordisk DKK 37.3B 5.86B Dec/2025
Novo Nordisk DKK 31.44B 6.84B Sep/2025
Pacira USD 49.36M 4.96M Sep/2025
Perrigo USD 258.8M 37.3M Sep/2025
Phibro Animal Health USD 30.48M 1.1M Sep/2024
Prestige Brands USD 90.82M 3.99M Dec/2025
Sanofi EUR 4.84B 2.95B Sep/2025
Supernus Pharmaceuticals USD 41.9M 432K Sep/2025
Zoetis USD 1.04B 87M Sep/2025